Cullinan Oncology Reels In $98M to Advance Cancer Drug Pipeline

Cullinan Oncology emerged nearly three years ago with an approach to cancer drugs its founders said would improve the odds of success. Now it has a pipeline of seven compounds and a fresh $98.5 million to advance all of them.